HK Stock Market Move | INNOVENT BIO(01801) rose more than 5% in the morning session, with a year-on-year increase in product revenue of 44.6%. The company achieved annual profitability for the first time.

09:55 27/03/2026

Xinda Biotech (01801) rose more than 5% in the morning session, up 5.48% as of the time of writing, to 83.75 Hong Kong dollars, with a trading volume of 474 million Hong Kong dollars.

INNOVENT BIO (01801) rose more than 5% in early trading, and as of the time of writing, it had increased by 5.48% to 83.75 Hong Kong dollars, with a trading volume of 4.74 billion Hong Kong dollars. On the news front, INNOVENT BIO released its annual performance report, with total revenue of 13.0415 billion Chinese yuan, a year-on-year increase of 38.4%. The company achieved annual profitability for the first time, with IFRS net profit of 814 million yuan, a significant improvement compared to a loss of 94.63 million yuan in 2024. In a financial review, product revenue was 11.896 billion yuan, a year-on-year increase of 44.6%, mainly due to the continued leading advantage in the field of oncology and the rapid expansion of the comprehensive product line. Although licensing revenue decreased to 957 million yuan (compared to 1.1 billion yuan in 2024), the strong overall revenue growth still drove the company's profitability. Non-IFRS net profit increased significantly to 1.723 billion yuan, a year-on-year increase of 419.6%.

ZHOU HEI YA (01458) has been issuing generous dividends to shareholders for three consecutive years, further increasing dividend payments and initiating a new round of share buybacks.

Throughout the year, ZIBUYU (02420) has continued to achieve record highs in performance, unleashing strong growth potential through "brand building."

HK Stock Market Move | CSTONE PHARMA-B(02616) surged by more than 20%, CS2009 lung cancer efficacy data impressive, may initiate first phase III MRCT this year.

ZHOU HEI YA (01458) has been issuing generous dividends to shareholders for three consecutive years, further increasing dividend payments and initiating a new round of share buybacks.

Throughout the year, ZIBUYU (02420) has continued to achieve record highs in performance, unleashing strong growth potential through "brand building."

HK Stock Market Move | CSTONE PHARMA-B(02616) surged by more than 20%, CS2009 lung cancer efficacy data impressive, may initiate first phase III MRCT this year.